| INTRODUCTION
The monoclonal antibody infliximab (IFX) neutralises the biological activity of the pro-inflammatory cytokine tumour necrosis factor (TNF) alpha. 1 When administered as scheduled intravenous infusions of 5 mg/kg body weight, IFX is effective for inducing and maintaining remission in patients with Crohn's disease (CD). 2, 3 Nevertheless, a significant proportion of patients who initially respond to IFX therapy experience secondary loss of response with symptom flares.
Defining loss of response as the need for dose escalation, Gisbert
and Pan es calculated a 13% annual risk for loss of response to IFX. 4 Intensification of the IFX treatment has been suggested as a strategy for regaining response. Modalities include increasing the dosing frequency (eg, from every 8 weeks to every 6 weeks), increasing the dose (eg, from 5 to 10 mg/kg body weight) and a combination of both. 5 Although an exposure-response relation has been identified, the rationale for treatment intensification is not well-defined since its effectiveness may depend on unrevealed underlying mechanisms like immunogenicity (ie, the production of antibodies towards IFX, ATI) or switch to a non-TNF driven disease mechanism. 6 Nevertheless, the ATI status at IFX failure did not significantly associate with clinical outcome of treatment intensification in several studies. 7, 8 A number of investigators have reported short-term clinical response rates to IFX treatment intensification between 59% and 96%. [9] [10] [11] [12] [13] [14] Yet, a significant proportion of patients does not regain clinical response after treatment intensification, which has to be taken into account when considering the potential safety issues and substantial drug cost that comes with treatment intensification. [15] [16] [17] Insight in the exposure and exposure-response relation may aid optimisation of cost-effectiveness of IFX treatment intensification. However, little is known about the course of IFX and ATI concentrations during treatment intensification and no data are available on how exposure and immunogenicity relate to response. 8 Furthermore, different intensification strategies appear to be equally effective. 9, 12, 14 No study has compared the pharmacokinetics and exposureresponse relation of the different treatment intensification strategies.
We investigated the possibility of tailoring IFX treatment intensification based on IFX and ATI concentrations, to guide physicians' clinical decision-making when a patient with CD experiences loss of response. Therefore, we studied IFX trough concentrations, ATI concentrations (measured using both a drug sensitive and a drug tolerant assay), short-term clinical and biological response and safety of different treatment intensification strategies.
| MATERIALS AND METHODS

| Overview
We conducted a retrospective review of medical records of all patients with CD at our institution who underwent serum sampling at trough (ie, just before IFX infusions). Medical records were searched to identify patients with CD who had received treatment intensification for clinical loss of response in our tertiary referral centre between 1 January 2000 and 1 October 2015. Loss of clinical response was defined as being no longer in remission based on physicians' global assessment of signs and symptoms. All patients included in the analysis had given written consent to participate in the Institutional Review Board approved inflammatory bowel disease (IBD) Biobank (B322201213950/S53684).
| Inclusion and exclusion criteria
All patients (1) with a diagnosis of CD (2) who were treated with IFX, (3) lost clinical response, (4) therefore received an IFX treatment intensification (ie, an IFX infusion at double dose -10 mg/kg body weight -and/or a next IFX infusion after a shortened interval) and (5) underwent blood sampling in two consecutive trough samples, taken just before (at T0) and after (at T+1) treatment intensification, were included in this retrospective study. Exclusion criteria were (1) IFX treatment intensification based on sub-therapeutic trough concentrations only, (2) episodic treatment and (3) treatment intensification during induction therapy.
| Measurements and analyses
IFX was measured at T0 and T+1 using an enzyme-linked immunosorbent assay (ELISA). 18 ATI were measured at T0 and T+1 using a drug sensitive ELISA (for measuring the concentration of free/unbound ATI) and a drug tolerant ELISA (using an acid dissociation step for measuring the concentration of both IFX bound and unbound ATI). 19, 20 Demographic, clinical and laboratory parameters from patients who met the entry criteria were abstracted from the electronic medical records. Parameters included sex, age, body weight, body length, smoking status, date of diagnosis of CD, date of first IFX infusion, serum albumin, C-reactive protein (CRP), haemoglobin and haematocrit at the studied time points T0 and T+1, clinical response at T+1, change in dose at T0 or dosing interval between T0 and T+1, comedication and adverse events within 1 year after T0.
Clinical response to IFX treatment intensification was defined as a marked decrease or disappearance of symptoms (physicians' global assessment). Biological response was evaluated in the subgroup of patients with an elevated CRP (>5 mg/L) before treatment intensification. Biological response was defined as a decrease from baseline CRP of at least 50% or a normalisation of CRP (≤5 mg/L). Biological remission was defined as a normalisation of CRP. Clinical and biological outcomes were evaluated at T+1.
Medical records were searched to assess IFX treatment discontinuation and safety issues up to 1 year after T0. between the different treatment intensification strategies (P = .144).
| Statistics
| Biological response
Treatment intensification resulted in short-term biological response in 25 patients (42%) and in short-term biological remission in 14 patients (24%). Biological response and remission rates did not differ between the intervention groups (P = .069 and P = .783 respectively). The median CRP at T0 as well as the proportion of patients with elevated CRP at T0 were not different between the three intervention groups (P = .680 and P = .094 respectively). There was a poor correlation between clinical response and biological response/ remission (P = .790 and P = 1.000 respectively).
3.3 | Pharmacokinetics
| Infliximab trough concentrations
The overall IFX trough concentration just before the treatment intensification (at T0) was 1.2 lg/mL [0. 3-3.7] (n = 94). In total, 64 patients (68%) had a T0 trough concentration below the therapeutic threshold of 3.0 lg/mL and IFX was BLQ in the T0 sample of 29 patients (31%) ( Table S1 ). The overall IFX trough concentration after the treatment intensification (at T+1) was 3.3 lg/mL [0.5-10.1]
(n = 102). IFX was still BLQ in the T+1 sample of 22 patients (22%).
A T0 trough concentration above 0.9 lg/mL (but below 3.0 lg/mL, n = 64) predicted a T+1 trough concentration ≥3.0 lg/mL (81% specificity, 64% sensitivity, AUROC 0.75, P = .002) ( Figure 1A ). Overall, interval shortening combined with dose doubling was more effective for optimising IFX trough concentrations than dose doubling alone, which in turn was more effective than interval shortening alone (P < .05) ( Figure 3A -C, Figure S1 , Table S1 ).
| Immunogenicity
Drug sensitive assay
Using the drug sensitive ELISA (for measuring the concentration of free/unbound ATI), 19% of all patients (n = 20) were identified with ATI at T0 (237 ng/mL eq. ). As this assay can only be used when IFX is BLQ, this indicates that 83% (20/24, five missing samples) of the BLQ IFX trough concentrations at T0 were driven by immunogenicity (Table S3) . When IFX was BLQ at T0, the absence of free ATI could not predict successful treatment intensification in terms of achieving a T+1 trough concentration ≥3 lg/mL (P = .624).
Drug tolerant assay
Using the drug tolerant ELISA (using an acid dissociation step for measuring the concentration of both IFX bound and unbound ATI), 47%
of all patients (n = 48) were identified with ATI at T0 (282 ng/mL eq.
[93-731]) (Table S1 ). The IFX trough concentration and ATI concentration in these samples were inversely correlated (n = 48, r = À.79, P < .0001). We observed a significantly lower incidence of ATI in patients combining IFX with an immunomodulator (10/39, 26%), compared to patients on IFX monotherapy (35/64, 55%) (P = .004).
After treatment intensification, ATI were quantified in the T+1 sample of 42 patients (503 ng/mL eq. [112-1158]) (of which 40
were also having ATI at T0). Only dose doubling resulted in a significant decrease in the ATI concentration (median change À82 ng/mL eq., P = .007, n = 16) (Table S1) .
A quantifiable ATI concentration below 282 ng/mL eq. at T0 predicted a post-treatment intensification trough concentration ≥3.0 lg/ mL (63% specificity, 75% sensitivity, AUROC 0.76, P = .003) (Figure 1B) . Treatment intensification was indeed effective for restoring therapeutic IFX trough concentrations when ATI before treatment intensification were absent or in the lowest quartile ( Figure S2a ).
When ATI were absent before treatment intensification (i.e., BLQ in the drug tolerant assay), all treatment intensification interventions were equally effective for restoring therapeutic trough concentrations ( Figure 3D , Figure S2b ). When ATI were quantifiable but low (below the 282 ng/mL eq. threshold), combined interval shortening and dose doubling was more effective for restoring therapeutic IFX trough concentrations than dose doubling alone, which in turn was more effective than interval shortening alone (P = .0005) and only dose doubling significantly increased the IFX trough concentration ( Figure 3E ). When ATI were high (above the 282 ng/mL eq. threshold), all treatment intensification interventions were equally ineffective for increasing the IFX trough concentration ( Figure 3F ).
Correlation between drug sensitive and drug tolerant assay
Only when IFX is BLQ, the drug sensitive assay can be used and therefore, only then it can be compared with the drug tolerant assay.
All patients with IFX BLQ at T0 who were ATI positive in the drug sensitive assay, were also ATI positive in the drug tolerant assay (Table S3) . Using the drug tolerant assay, two patients who were ATI negative in the drug sensitive assay were now identified as ATI positive. Of these two patients, only the one that underwent combined interval shortening and dose doubling obtained a therapeutic trough concentration at T+1, but the one that underwent interval shortening did not. We observed a good correlation between ATI concentrations in the drug sensitive and the drug tolerant assay (n = 23, r = .87, P < .0001).
| Predictors of restored exposure
A higher IFX dose, a shorter dosing interval and ATI below the 282 ng/mL eq. threshold are independent predictors of a restored therapeutic trough concentration (Table S4 ). The T0 IFX trough concentration was not withheld as an independent predictor (direct nor via interaction effect) of the outcome ( Figure S3 ). An interaction between ATI and dose was withheld during automated model selection (model 6, AIC c within two units from model 1). However, this negative influence of ATI on the effectiveness of a higher dose on the probability of restoring therapeutic trough concentrations was not statistically significant (P = .285).
| Exposure-response correlation
Post-treatment intensification trough concentrations were comparable for patients with and without clinical response (P = .198) (Figure 4) . Instead, patients with biological response and remission had significantly higher trough concentrations after treatment intensification, compared to patients with no biological response and remission (P = .002 and P = .026, respectively). Furthermore, biological response was associated with a higher proportion of patients achieving a therapeutic trough concentration after treatment intensification (15 of 24; 63%) compared to biological nonresponse (9 of 35; 26%) (P = .007).
A T0 IFX trough concentration above the 0.9 lg/mL threshold was not associated with a higher response rate (clinical nor biological) compared to a T0 IFX trough concentration below the 0.9 lg/ mL threshold (P>.050) (Table S5 ). Nevertheless, a T0 ATI concentration below the 282 ng/mL eq. threshold was associated with a higher clinical response rate (45 of 64; 70%) compared to a T0 ATI concentration above the 282 ng/mL eq. threshold (11 of 24; 46%) (P = .034) (Table S5 ).
| One-year follow-up
Of the 65 patients experiencing clinical response at T+1, 51 (78%) were still on infliximab therapy 1 year after T0; 23/33 (70%) after interval shortening, 21/24 (88%) after dose doubling and 7/8 (88%) after combined interval shortening and dose doubling. These proportions were similar (P = .218) ( Figure 5 ). . T0 ATI concentration thresholds of 282 ng/mL eq. (63% specificity, 75% sensitivity) and 498 ng/mL eq. (50% specificity, 100% sensitivity) are calculated using the "closest top-left" method and the Youden's J statistic, respectively. The 282 ng/mL eq. threshold was selected as this coordinate lies closer to the smoothed ROC curve than the 498 ng/ mL eq. threshold. Moreover, the higher specificity associated with the 282 ng/mL eq. threshold is more relevant from a medical perspective (ie, the higher success rate of treatment optimisation when a patient has an ATI concentration below the threshold)
| Safety
Medical records of the 103 patients were examined for safety data up to one year after receiving IFX treatment intensification. Ten adverse events, none requiring hospitalisation, occurred in nine patients (Table S6) . One patient died 7 months after the IFX interval shortening, following a sudden cardiac arrest of unknown origin. We assessed an overall short-term clinical response rate of 63% after treatment intensification and clinical response rates T+1  T0  T+1  T0  T+1  T0  T+1 **** **** **** *** F I G U R E 2 The change in infliximab trough concentrations before (T0) versus after (T+1) treatment intensification. The changes in infliximab trough concentrations were evaluated using the Wilcoxon matched-pairs signed rank test. DD: dose doubling; IS: interval shortening; n: number of patients with both pre-and post-treatment intensification infliximab trough concentration available. Trough concentrations are represented as median [interquartile range]. ***P < .001, ****P < .0001
| DISCUSSION
IS ATI BLQ at T0 Quantifiable ATI < 282 ng/mL eq. at T0 ATI ≥ 282 ng/mL eq. at T0
Infliximab <3 µg/mL at T0 Infliximab ≥0.9 µg/mL and <3 µg/mL at T0 Infliximab <0.9 µg/mL at T0 
The effect of the different treatment intensification strategies on achieving an infliximab trough concentration ≥3.0 lg/mL. The proportion of patients who achieved an infliximab trough concentration ≥3.0 lg/mL at T+1, in the subgroup of patients with infliximab at T0 (A) <3.0 lg/mL, (B) ≥0.9 lg/mL and <3.0 lg/mL and (C) <0.9 lg/mL, or with antibodies towards infliximab at T0 (D) below the limit of quantification, (E) quantifiable but <282 ng/mL eq. and (F) ≥282 ng/mL eq. Differences in proportions were evaluated using the Fisher's exact test/a trend in proportions (IS < DD < IS+DD) was evaluated using the 2-sided Cochrane-Armitage trend test. DD: dose doubling; IS: interval shortening. *P < .05, **P < .01, ***P < .001, ****P < .0001, ns: not significant 
The correlation between clinical response and biological response and remission and the change in infliximab trough concentrations before vs after treatment intensification. The change in infliximab trough concentrations was evaluated using the Wilcoxon matchedpairs signed rank test. The differences in post-treatment infliximab trough concentrations were evaluated using the Mann-Whitney U test. n: number of patients with both pre-and post-treatment intensification infliximab trough concentration available. *P < .05, ***P < .001, ****P < .0001 were similar for dose doubling and interval shortening, which is in line with reports made in literature. In our study, 68% (64/94) of the patients had a T0 trough concentration below 3 lg/mL, which is similar to the 64% (16/25) reported by Hendler et al 13 There is only one study by Suzuki et al where both the T0 (median 0.3 lg/mL, n = 39) and T+1 (8 weeks later, median 1.29 lg/mL, n = 33) trough concentrations are reported for patients undergoing IFX dose doubling. 31 Hibi et al showed that interval shortening from eight to 4 weeks increased the trough concentration to 4.9 lg/mL at T+1 (T0 trough concentration not reported). 32 Furthermore, exposure-response relations have been investigated by a few other authors with variable success, mostly due to the low sample size. 8, 13, 31, 32 However, due to different study set-ups (assay formats, sampling and evaluation times, outcome measures), comparison with our results is difficult.
Suzuki et al detected ATI in 5% (2/39) of the T0 samples using a drug sensitive assay that does not allow the detection of ATI in the presence of free IFX. 31 Steenholdt et al detected ATI in 32% (13/41) of the patients using a drug tolerant homogeneous mobility shift assay. 8 In our study, we observed ATI at a much higher rate of 19% (20/103) using the drug sensitive assay and of 47% (48/103) using the drug tolerant assay that allows the detection of ATI in the presence of free IFX (up to at least 10.0 lg/mL). 19 While the drug sensitive assay can only be used when IFX is BLQ, the drug tolerant assay can detect ATI in the presence of free IFX molecules. Therefore, the drug sensitive and drug tolerant assays come into play in different contexts and should not be considered interchangeable.
Only when IFX is BLQ, both assays can be used. In this specific situation (29 patients, 28%), both assay results show a strong correlation.
The drug tolerant ATI assay may be especially useful in situations where IFX is detectable (74 patients, 72%). In our study, when considering all ATI concentrations measured using the drug tolerant assay (independent of the IFX concentration, detectable or not), we observed a higher ATI concentration at T0 in those patients who did not obtain a T+1 trough concentration ≥3 lg/mL compared to those patients who did obtain a therapeutic T+1 trough concentration.
In addition, we investigated a potential role for measuring IFX and ATI in the framework of clinical decision support on treatment intensification strategies. Since the IFX trough concentration and the ATI concentration (measured using the drug tolerant assay) at T0 are strongly correlated, TDM might as well be based on IFX trough concentrations alone. However, two patients might have the same T0 trough concentration, but treatment intensification might turn out differently when one patient has ATI and the other one has not. Larger cohorts need to be studied to explore the comparative (cost) effectiveness of TDM based on IFX and/or ATI concentrations.
Our data support a role for measuring ATI concentrations in the context of "reactive" TDM (ie, for regaining response). However, with turnaround times of at least a few working days, it is not possible to act upon the measurement at the time the sample is taken, hampering an efficient clinical implementation of reactive TDM.
Therefore, we suggest performing TDM in a "proactive" manner (ie, for preventing loss of response) and when loss of response strikes, we recommend performing dose doubling over interval shortening. 33 In the foreseeable future, the development of point-of-care assays will allow on-site availability of the analytical result and therefore improve flexibility of both proactive and reactive TDM. 
